Veradermics (NYSE: MANE) reported that its extended-release oral minoxidil tablet, VDPHL01, met all primary and key secondary endpoints in a Phase II/III trial in male pattern hair loss, with hair count gains roughly four times those seen with placebo at six months.
Study "302" is a randomized, double-blind, placebo-controlled Phase II/III trial enrolling 519 men with mild-to-moderate androgenetic alopecia, comparing VDPHL01 8.5 mg once daily, VDPHL01 8.5 mg twice daily, and placebo.
At Month 6, mean non-vellus target area hair count increased by 30.3 hairs/cm² with once-daily dosing and 33.0 hairs/cm² with twice-daily dosing, against 7.3 hairs/cm² for placebo (both p<0.0001). On the co-primary patient-reported outcome, 48.4% and 62.9% of patients in the once-daily and twice-daily arms, respectively, rated their hair coverage as "improved" or "much improved" on the Androgenetic Alopecia Impact Rating Scale, versus 13.4% in the placebo group (both p<0.0001). Investigators graded 72.0% and 84.4% of patients in the respective active arms as improved. Statistically significant separation from placebo on both hair count and investigator assessment appeared as early as Month 2. Treatment-emergent adverse event rates were similar between VDPHL01 and placebo, with no treatment-related serious adverse events and no cardiac adverse events of special interest recorded through six months.
The molecule at the center of these results is not new. Minoxidil has been used topically for androgenetic alopecia since the late 1980s, when the FDA approved a 2% solution, followed by a 5% foam formulation around 2006. Oral minoxidil has been used off-label for hair loss for years, but it carries recognized cardiovascular risks — fluid retention, tachycardia, and pericardial effusion — that have constrained its uptake, particularly at doses high enough to produce meaningful hair growth. Veradermics' argument is that its proprietary gel-matrix extended-release technology changes that calculus by flattening the plasma concentration curve, reducing peak exposure while extending the time minoxidil remains above the threshold thought to stimulate follicular activity. The company positions this pharmacokinetic profile as the basis for efficacy without the cardiac concentration spikes associated with immediate-release oral formulations.
Whether that pharmacokinetic rationale translates into a clinically distinct safety advantage over off-label oral minoxidil remains to be established through direct comparison. The Study "302" data show a favorable tolerability profile against placebo, but the trial was not designed to compare VDPHL01 against immediate-release oral minoxidil, and cross-trial comparisons are limited by differences in populations, doses, and endpoints. What the data do establish is that an extended-release oral minoxidil formulation can produce statistically robust hair count gains in a controlled Phase II/III setting, with a safety signal that did not deviate meaningfully from placebo over six months.